{"id":"W3029319309","doi":"10.1200/jco.2020.38.15_suppl.tps9076","title":"Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Nivolumab; Internal medicine; Oncology; Stage (stratigraphy); Adjuvant; Randomized controlled trial; Population; Chemotherapy; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001132923,0.00102756,0.0009995474,0.000351099,0.0002775466,0.001296768,0.0009537871,0.001192863,0.007716883],"category_scores_gemma":[0.0008796058,0.0003514499,0.001317623,0.0002760431,0.0006007536,0.0007007569,0.0003794182,0.002599709,0.00134735],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001160518,"about_ca_system_score_gemma":0.00130461,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001564927,"about_ca_topic_score_gemma":0.005782691,"domain_scores_codex":[0.9997852,0.00009063957,0.000008948329,0.00003074822,0.00002761333,0.00005682637],"domain_scores_gemma":[0.9996785,0.00005518453,0.0000697647,0.00002410811,0.000015659,0.0001568663],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6055259,0.03334606,0.004505846,0.004251213,0.00271619,0.0002887023,0.000321818,0.005018691,0.03867467,0.001872954,0.03217369,0.2713041],"study_design_scores_gemma":[0.7561694,0.2141815,0.007609213,0.0003137319,0.001043978,0.0003201256,0.00008675544,0.00224119,0.004170501,0.0005907352,0.01321324,0.00005967865],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9573569,0.01573323,0.0009888944,0.002648747,0.001312951,0.003900361,0.004295168,0.0005004273,0.01326344],"genre_scores_gemma":[0.9539136,0.009119966,0.002765537,0.00555039,0.0004777247,0.004723052,0.008636039,0.0001201324,0.01469359],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007716883,"threshold_uncertainty_score":0.02581561,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.104702518185856,"score_gpt":0.4519634046092852,"score_spread":0.3472608864234292,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}